Treatment non-Hodgkin’s lymphoma in Germany
Innovative therapy protocols: from precise diagnostics to cellular technologies
Non-Hodgkin’s lymphoma is a heterogeneous group of malignant diseases of the lymphatic system, including more than 60 subtypes. RheinRegio Klinik Zentrum uses personalized treatment regimens based on immunophenotyping and molecular genetic characteristics of the tumor. Our goal is to achieve long-term remission even in aggressive forms of NHL.
Symptoms non-Hodgkin’s lymphoma
Typical manifestations
- Painless enlargement of lymph nodes (cervical, axillary, inguinal)
- “B-symptoms”:
- Night sweats (profuse)
- Fever >38°C without infection
- >10% weight loss in 6 months
Extranodal lesions
- Stomach: dyspepsia, pain
- CNS: headaches, paresis
- Skin: itchy patches/nodules
Important: In 20% of patients, the first symptom is only increased fatigue.
Diagnostics non-Hodgkin’s lymphoma at the RheinRegio Klinik Zentrum
At RheinRegio Klinik Zentrum we carry out:
- Excisional lymph node biopsy with:
- Immunohistochemistry (CD20, CD3, CD30)
- Fluorescent hybridization (MYC, BCL2, BCL6)
- Whole body PET-CT (staging standard)
- Trephine biopsy of bone marrow
- Molecular tests:
- Next Generation Sequencing (NGS)
- PD-L1 status (for immunotherapy)
Innovation: Analysis of circulating tumor DNA for early detection of relapses.
Each direction is supervised by advanced oncologists.
Find out the cost of treatment
To find out the approximate cost of treatment, answer a few questions and we will contact you!
Classification and stages non-Hodgkin’s lymphoma
Main types
- B-cell (85% of cases):
- Diffuse large B cell (DLBCL)
- Follicular lymphoma
- Mantle cell
- T cell:
- Peripheral T cell
- Anaplastic large cell
Ann Arbor Stages
- I: Lesion of 1 group of lymph nodes
- III: On both sides of the diaphragm
- IV: Bone marrow/other organ involvement
Example: Stage II DLBCL with extranodal involvement of the stomach.
Treatment methods non-Hodgkin’s lymphoma
1. Chemotherapy
- R-CHOP (rituximab + cyclophosphamide) – gold standard for DLBCL
- Bendamustine + rituximab – for follicular lymphomas
2. Targeted therapy
- Ibrutinib (for mantle cell lymphoma)
- Polatuzumab vedotin (CD79b-targeted)
3. Immunotherapy
- CAR-T cells (tisagenlecleucel for refractory forms)
- Bispecific antibodies (blinatumomab)
4. Radiation therapy
- IFRT (for local lesions)
Survival prognosis
- Aggressive NHL: 5-year survival rate 60-70%
- Indolent forms: median 8-10 years
- Recurrent cases: 40% response to CAR-T
Risk factors:
- High IPI (International Prognostic Index)
- Double/triple hit mutations
Why choose Germany?
- Leader in hemato-oncology – 5-year survival rate is 15% higher than the world average
- Financial transparency – fixed course price
Conclusion
At the RheinRegio Klinik Zentrum, each patient with NHL is offered an individual treatment plan developed by a multidisciplinary team.
Sign up for a consultation – we are ready to help even in difficult cases!
Our clinics
The association of clinics RheinRegio Klinik Zentrum offers treatment organization non-Hodgkin’s lymphoma in Germany without intermediaries, providing access to the country’s leading oncology clinics. We combine advanced techniques, an individual approach and the highest level of medical care, giving hope even in difficult cases.
Why RheinRegio Klinik Zentrum?
- Reference center for lymphomas – participation in studies (GOYA, SCHOLAR-1)
- Clinic-based production of CAR-T cells
- Genetic passport of a tumor – selection of therapy based on mutations
- Patient support – nutritional and psychological assistance
